Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JPMA President Hints at Adoption of Unified System to Disclose Fees Paid to Doctors Next Year
July 25, 2014
-
BUSINESS Ono, BMS Announce Strategic Alliance for 5 Immuno-Oncology Products
July 25, 2014
-
BUSINESS Astellas Gears Up to Accelerate R&D
July 24, 2014
-
REGULATORY Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago
July 23, 2014
-
BUSINESS Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
-
BUSINESS Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014
July 18, 2014
-
BUSINESS Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President
July 17, 2014
-
BUSINESS Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo
July 16, 2014
-
BUSINESS Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient
July 15, 2014
-
BUSINESS “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel
July 14, 2014
-
REGULATORY Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
-
BUSINESS Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016
July 11, 2014
-
BUSINESS Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
-
BUSINESS Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
-
BUSINESS MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
-
BUSINESS Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
-
BUSINESS Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
-
REGULATORY MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
-
BUSINESS Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
July 3, 2014
-
BUSINESS Pfizer Japan to Diversify Revenue Streams to Maintain Growth in “Post-Lipitor Era”: President
July 2, 2014
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…